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Abstract 
The Ca2+-binding protein S100AI displays a tissue-specific expression pattern with highest levels in myocardium and has been shown 
to interact with SR-proteins regulating the Ca2+-induced Ca2+-release. We, therefore, hypothesized that changes in S100A1 gene 
expression might correlate with the pathognomonic f nding of altered SR Ca2+-transients in human end stage heart failure. To test this 
hypothesis, we established a specific and sensitive method to analyse S100AI expression i  cardiac tissues by employing hydrophobic 
interaction-chromatography nd reversed-phase high performance liquid chromatography (RP-HPLC) coupled with Electron-Ionisation- 
Mass-Spectrometry (ESI-MS). Porcine myocardium showed a differential expression of S100AI with relative protein concentrations of 
62 + 8% in the fight ventricle (RV), 57 _ 9% in the right atrium (RA), and 25 +__ 15% in the left atrium (LA) as compared to the left 
ventricle (LV) (100 ___ 10%; P < 0.001). Northern blot analyses confirmed a likewise distribution of porcine S100A1 mRNA implying a 
regulation on the transcriptional level. Analyses of left ventricular specimen of patients with end stage heart failure (CHF, n = 6; CHD, 
n = 6) revealed significantly reduced SI00A1 protein levels, while integration of S100A1 peaks after RP-HPLC yielded two groups of 
patients with < 76% (69 + 7%, n = 6) and < 35% (23 -t- 12%, n = 6) respectively as compared to controls (100 ___ 8%, n = 3). These 
data demonstrate for the first time that S100A1 is differentially expressed in myocardium and that in human cardiomyopathy a reduced 
expression of S100A1 may contribute to a compromised contractility. 
I. Introduction 
A reversed force-frequency relationship [1] and an al- 
tered Ca/--handling [2,3] are characteristic findings in 
human end stage heart failure. Thus an altered expression 
of sarcolemmal (SL) L-type channels, the SR Ca 2 +-ATPase 
(SERCA 2) and SR-Ca2+-release-channels were proposed 
as possible molecular mechanisms underlying an altered 
Ca2÷-cycling. While the expression of L-type channels 
does not seem to be affected in human cardiomyopathy [4], 
different authors reported on decreased SERCA 2, phos- 
pholamban and SR-Ca2+-release-channel mRNA levels in 
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both human [5,6] and experimental [7] cardiomyopathy. 
Whether the observed reduction of gene expression is 
translated into reduced protein concentrations i  however 
still a matter of controversy, since Movsesian et al. [8] 
found unchanged protein levels for SERCA 2 and phos- 
pholamban. However, a decreased activation and thus al- 
tered regulation of SERCA 2 and the SR-Ca2+-release - 
channel could account for changes in CaZ+-cycling. Be- 
cause the cAMP-dependent phosphorylation of phospho- 
lamban is a prerequisite for the activation of SERCA, 
reduced cAMP levels, as found in human end-stage heart 
failure [9] and various experimental settings of experimen- 
tal hypertension [10], might explain a reduced activation of 
SERCA. 
Not much attention has been paid so far to the hypothe- 
sis that Ca2+-binding proteins might play a central role in 
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the setting of an impaired Ca2+-cycling in human car- 
diomyopathy. Jeck et al. [11] showed that calmodulin 
mRNA levels are reduced in human cardiomyopathy. This 
protein is known to activate several protein kinases, Ca 2 +- 
ATPases, and adenylyl cyclases. One may therefore specu- 
late that a reduced calmodulin expression correlates with 
the observed impairment of Ca2+-homeostasis. But since 
to date no protein data are available as far as human heart 
failure is concerned an interpretation f this finding would 
not be conclusive. 
S100 proteins, constituting the largest subfamily of 
EF-hand proteins in the realm of Ca2+-binding proteins, 
elicit numerous Ca2+-dependent i racellular effects such 
as the modulation of cell cycle progression, cell differenti- 
ation, protein phosphorylation, and signal transduction 
[12,13]. One of the S100 family members, S100A1, shows 
a tissue-specific expression-pattern with highest concentra- 
tions in cardiac muscle [14]. Since it has been shown that 
S100A1 modulates adenylyl cyclase (AC) activity [15], 
Ca 2 +-induced Ca 2 +-release [ 16], and microtubule assembly 
[17] we hypothesized that an altered expression of S100A1 
might account for pathophysiological findings in human 
cardiomyopathy such as reduced cAMP-levels [9], diastolic 
Ca2+-overload [18], and an increased viscous load [19]. 
We therefore investigated the expression of SI00A1 in 
cardiomyopathic and control hearts. As to our knowledge 
we report for the first time about a differential expression 
of SI00A1 in myocardium as well as about a downregula- 
tion of this protein in human cardiomyopathy. 
2. Materials and methods 
2.1. Materials 
Porcine hearts were purchased from the local slaughter- 
house. All human cardiac tissues were obtained from 
patients undergoing elective orthotopic heart transplanta- 
tion due to ischemic (CHD, n = 6) and dilative (CHF, 
n = 6) cardiomyopathy. All patients investigated belonged 
to NYHA group IV receiving the usual medication i clud- 
ing digitalis, ACE-inhibitors, diuretics and nitrates. None 
of the patients was treated with /3-blockers or catechol- 
amines. None of the myopathic specimen showed any 
histopathological signs of inflammation. Nonfailing con- 
trois (n = 3) derived from hearts 5-8 h post mortem from 
patients who died from cerebral haemorrhage. Experiments 
were performed after written informed consent according 
to the Helsinki-Declaration a d were approved by the local 
Ethics Committee. 
2.2. Protein analyses 
Myocardial samples (--~ 100 mg) were homogenised in
5 volumes (v/w) of extraction-buffer (mmol/l: 25 imida- 
zole, pH 7.5, 5 EDTA, 0.1 PMSF), stirred for 15 min at 
4°C, and centrifuged (50000 × g for 15 rain). Pellets were 
reextracted in 3 vol (v/w) and supernatants pooled. Total 
protein content was adjusted to 1 mg/ml, before equal 
amounts of supernatants were brought o 50% ammonium- 
sulfate and equilibrated for 30 min at RT. After centrifuga- 
tion (50000 × g for 15 min) equal amounts of the resul- 
tant supernatants were loaded on Octylsepharose (Phar- 
macia) equilibrated with loading-buffer (mmol/l: 2 CaC12, 
25 imidazole, pH 7.0; 0.5 ml/min). After washing the 
column with 15 vol of loading-buffer, a stepwise gradient 
was run with elution-buffer (mmol/l: 5 EGTA, 25 imida- 
zole, pH 9.0). Equal volumes of eluting Ca2+-binding 
protein pools were gathered as detected at 280 nm. Finally 
Ca 2 +-binding protein pools were acidified (final concentra- 
tion 3% acetic acid) and fractionated on a reverse-phase 
C8 column (Brownlee, Aquapore RP-300, 300 X 2.1 ram, 
7/x) as described by Pedrocchi et al. [20]. UV monitoring 
was performed at 220 nm. A profile integrator was used to 
determine the relative protein amounts. Online Electron- 
Ionisation-Mass-Spectrometry (ESI-MS) was performed 
with a Sciex API III instrument (Perkin Elmar/Sciex, 
Thornton, Canada) equipped with an ion spray source as 
described [20]. 
2.3. RNA-analyses 
Total RNA was isolated from cardiac tissue using a 
single-step extraction procedure according to the instruc- 
tions of the manufacturer (RNA-clean, Angewandte Gen- 
technologie Systeme, Heidelberg, Germany). 10 /zg RNA 
of each specimen were fractionated on a 1% agarose-gel 
containing 6% formaldehyde and transferred to a Nylon N 
membrane (Schleicher and Schuell, Dassel, Germany) by 
diffusion-blotting according to standard procedures. After 
crosslinking by UV radiation hybridisation was performed 
for 1 h at 68°C using Quick-Hybrid-Solution (Stratagene, 
La Jolla, Ca, USA) containing 100 /xg/ml salmon-sperm 
DNA and 1.5 × 10 6 cpm/ml radiolabeled (Rediprime, 
Amersham, Cleveland, OH, USA) human S I00AI-cDNA 
(GenBank/EMBL $46852) probe. Membranes were 
washed thereafter 2 × 15 min at room temperature with 
1 × SSC, 0.1% SDS and eventually for 30 min at 60°C 
with 1 × SSC, 0.1% SDS. BioMax MS Kodak films were 
exposed for 2-7 days. S100A1 mRNA signals were cor- 
rected for 28S signals. 
2.4. Statistical analyses 
Three tissue samples of each heart and location were 
extracted and analysed separately. The mean value of the 
nine porcine left ventricular specimen was set 100%, as 
was the mean value of nine human control specimen. A 
profile integrator was used to evaluate the relative S 100A1 
protein amounts eluting from RP-HPLC. Protein amounts 
are therefore given as % _+ SEM of control value (unpaired 
Student's t-test). 
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3. Results and discussion 
Comparative studies [21l] revealed significant differ- 
ences among species as to the expression levels of the 
S100AI protein in myoeardium. Since porcine my- 
ocardium shows the highest expression level of this con- 
served protein, purification procedures were established 
with this tissue. 
Most authors exploit the hydrophobic interaction of 
Ca2+-binding proteins with phenylsepharose upon Ca2+-bi - 
nding. Due to the pronounced hydrophobicity of S100 
proteins, however, the use of this matrix leads to consider- 
able protein losses, when elution is achieved by an EGTA 
gradient, thus hindering quantitative xpression studies. 
Since stronger eluents such as organic solvents would 
interfere with a following reverse-phase chromatography, 
we chose octylsepharose displaying a less pronounced 
hydrophobic interaction and allowing a nearly quantitative 
elution of the Ca2+-binding protein pool by a combined 
EGTA/pH step-gradient. In order to exclude sampling 
errors which might occur with differing levels of fibrosis 
protein extracts were corrected for total protein content 
and equal amounts and volumes were used for chromatog- 
raphy. 
Fig. 1 shows representative chromatograms of porcine 
cardiac Ca2+-binding protein pools after RP-HPLC frac- 
tionation. Online ESI-MS analyses of porcine CaBP docu- 
mented two major protein fractions (Fig. 1). Calmodulin 
(1) and S100A1 (2) were identified by Western blotting 
employing monoclonal antibodies and by ESI-MS reveal- 
ing molecular masses of 16789 Da and 10427 Da (porcine), 
respectively. Another minor fraction eluting between 
calmodulin and S100A1 represented the CaBP S100C (*) 
as identified by its molecular mass of 11 092 Da being 
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Fig. 1. Representative RP-HPLC chromatograms are shown for Ca2+-bi - 
nding protein pools from porcine heart. Left ventricle (LV), fight ventri- 
cle (RV), right atrium (RA), and left atrium (LA). Calmodulin (1) and 
S100AI (2) eluted with 50% and 56% elution buffer (0.08% TFA, 80% 
acetinitrile) respectively. S100C ( * ) eluted as a minor fraction with 52% 
elution buffer. The mean value of 9 independently analysed LV specimen 
was set 100%. As compared to the LV (100+-10%), RV (62_8%, 
n = 9), RA (57 +9%, n = 9), and LA (25+_ 15%, n = 9) revealed signifi- 
cantly lower S100A1 protein concentrations (P  < 0.001). Interestingly 
calmodulin content appeared to be highest in LA. 
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Fig. 2. Northern blot analysis of porcine myocardial specimen unveils a 
likewise distribution fS100A1 mRNA as compared to protein distribu- 
tion. Left ventricle 100+_14% (LV, n= 11), right ventricle 45+_ 16% 
(RV, n= 10), right atrium 47+29% (RA, n=ll), and left atrium 
22+7% (LA, n=8). A human S100A1 cDNA was used to detect 
porcine S100A1 mRNA, while signals were corrected for 28S RNA. 
N-acetylated after cleavage of the N-terminal methionine 
(calculated mass: 11179 Da; Swiss Prot, acc. no. P31950). 
Quantifying the eluting S100A1 protein amounts revealed 
a differential expression of this protein in myocardium. 
The right ventricular (62 + 8%), right atrial (57 4-9%), 
and left atrial (25-4-_ 15%) tissues showed significantly 
lower S100A1 levels as compared to the left ventricle 
(100 + 10%; P < 0.001). Additional analyses unveiled a 
homogenous transmural distribution of S100AI protein 
(data not shown). Northern blot analyses (Fig. 2) docu- 
mented a likewise distribution of porcine S100AI-mRNA 
amounting to 45 +_ 16% in RV (n = 10), 47 _+ 29% in RA 
(n = 11), and 22 _+ 7% in LA (n = 8) as compared to the 
left ventricle (100 + 14%, n = 11). This implies a S100A1 
gene regulation on the transcriptional level, as it has been 
shown for S100A6 [22]. 
Interestingly a differential expression has also been 
reported for /3-receptors in bovine [23] and for phospho- 
lamban in mice myocardium [24] resulting in higher pro- 
tein concentrations in ventricular tissues. Together with 
these findings the differential expression of SI00A1 in 
myocardium might therefore reflect a coordinate gene 
expression as to specialized ifferences concerning Ca 2+- 
cycling of atria and ventricles. 
In order to investigate SI00A1 expression i human end 
stage heart failure left ventricular specimen (taken from 
the free wall of explanted hearts) from 12 patients were 
analysed. In these patients orthotopic heart transplantation 
was performed ue to ischemic heart disease (CHD, n = 6) 
and to dilative cardiomyopathy (CHF, n = 6). ESI-MS 
analyses confirmed identical molecular masses for S100A1 
(calculated mass: 10547 Da; GenBank/EMBL, acc.no. 
$46852) in CHD (10459 ± 1.25 Da), CHF (10459 4- 1.23 
Da) and controls (10460 +_ 1.15 Da) yielding evidence that 
posttranslational processing of S100A1 is not altered in 
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Fig. 3. RP-HPLC fractionation of human left ventricular CaBP pools are 
shown. (a) control LV specimen, (b) group of myopathic specimen 
revealing < 76% (69+7%; CHF, n = 4; CHD, n = 2), and (c) < 35% 
(23 :t: 12%; CHF, n = 2; CHD, n = 4) as compared to control group A 
(100+ 8%; P < 0.001). ESI-MS analysis: (1) calmodulin 16794+ 1.64 
Da; (2) HbA 15870+2.56 Da; (3) HbB 15129+1.93 Da; (4)+(5) 
S100A1 10460+ 1.15 Da in control tissue (a). Fraction 5 might represent 
an S100Al-dimer fraction disassembling during ESI-MS analysis. 
Calmodnlin and S100A1 showed identical retention times as the respec- 
tive porcine proteins. 
cardiomyopathy. As has been shown by Pedrocchi et al. 
[20] the posttranslational modification is confined to an 
N-terminal acetylation resulting in a mass correction of 
-89  (methionine: -131;  acetyh +42). Since a minor 
fraction of S100A1 eluting in peak 5 (Fig. 3) reveals an 
identical molecular mass as the main fraction in peak 4 
(Fig. 3), it might represent an S100Al-dimer fraction 
disassembling during ESI-MS analysis. As compared to 
control tissues (100+ 8%, n= 3) all cardiomyopathic 
samples howed significantly reduced S100A1 protein lev- 
els (P  < 0.001), whereas two groups could be identified 
with < 76% (69 ___ 7%) and < 35% (23 + 12%), respec- 
tively. No correlation however could be established be- 
tween one of these groups with the underlying disease or 
with the left ventricular enddiastolic pressure. This might 
either be due to the small number of specimen analysed or 
to the fact that the small samples might not have always 
been representing the whole transmural cross-section. Since 
a cAMP dependent gene expression is being discussed for 
S 100A1 [25] and the observed ownregulation f /3-recep- 
tors in human end stage heart failure is most pronounced 
in subendocardial tissue [26], this might have introduced a 
methodical error. But nevertheless S100Al-protein levels 
were significantly diminished in both groups and thus 
might explain several findings in human end stage heart 
failure. Fano et al. [16] reported that S100A1 protein 
stimulates the Ca2+-induced Ca2+-release from SR in the 
presence of Mg 2+ in porcine heart. Since a reduced Ca 2+- 
induced Ca2+-release from SR is documented for the 
failing human heart, a downregulation of S100A1 would 
be in line with this finding. Moreover the same authors 
reported about the modulation of the basic adenylyl cy- 
clase activity by S100A1 in skeletal muscle. But since we 
could not detect any effect on the adenylyl cyclase activity 
by S100A1 employing cardiac membrane preparations 
(Greten et al, manuscript in preparation), the low cAMP 
levels in cardiomyopathy obviously do not correlate with 
our finding of diminished S100A1 protein levels. Experi- 
ments as to the viscoelasticity of the failing heart have 
revealed an excess forming of microtubules impeding sar- 
comere motion by increasing the viscous load [19]. Be- 
cause Donato et al. [17] demonstrated an inhibition of 
microtubule assembly by S 100A 1, decreased S 100A 1 pro- 
tein levels might represent a molecular explanation for the 
observed hyperpolymerization of tubulin molecules in car- 
diomyopathy. To date it is however not clear whether this 
is only an unspecific effect of S100A1, since this has also 
been reported for calmodulin [27]. Another interesting 
hypothesis arises from gel-overlay experiments performed 
by Zimmer [28] who found an interaction of S100A1 with 
different SR-proteins. Among these, two molecules with a 
mol wt. of 30 kDa and 100 kDa interacted with S100A1 
representing the phospholamban pentamere and possibly 
the SERCA 2 molecule, respectively. This raises the hy- 
pothesis that S100A1 not only modulates the CaZ+-induced 
Ca2+-release from SR but might also regulate the seques- 
tration of cytosolic Ca 2+ into the SR. If this holds true, 
which is currently under investigation, S100AI would 
indeed be an interesting candidate to explain the altered 
Ca 2 +-handling in end stage heart failure. 
The differential expression of S100A1 in porcine heart 
might reflect specialized ifferences of atrial and ventricu- 
lar tissues concerning Ca2+-cycling, while the observed 
downregulation of this protein is in line with several 
findings in human cardiomyopathy. The ascribed cellular 
functions of S 100A1 however are mostly in vitro findings. 
Therefore additional studies as to the physiological rele- 
vance of an altered gene expression of S 100A 1 are needed. 
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